EAM Investors’s Harvard Bioscience HBIO Stock Holding History

EAM Investors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,499	Closed	-$1.13M	–	319
2023 Q2	$1.13M	Sell	20,499 -14,056	-41%	-$771K	0.21%	219
2023 Q1	$1.45M	Buy	+34,555	New	+$1.03M	0.29%	180
2021 Q4	–	Sell	-17,058	Closed	-$1.19M	–	319
2021 Q3	$1.19M	Sell	17,058 -3,641	-18%	-$290K	0.2%	242
2021 Q2	$1.72M	Hold	20,699	–	–	0.27%	166
2021 Q1	$1.13M	Buy	+20,699	New	+$1.01M	0.17%	287
2018 Q4	–	Sell	-26,608	Closed	-$1.4M	–	276
2018 Q3	$1.4M	Buy	26,608 +15,401	+137%	+$864K	0.21%	172
2018 Q2	$600K	Sell	11,207 -2,047	-15%	-$105K	0.09%	272
2018 Q1	$663K	Buy	+13,254	New	+$594K	0.11%	246
2015 Q2	–	Sell	-26,944	Closed	-$1.57M	–	343
2015 Q1	$1.57M	Buy	+26,944	New	+$1.45M	0.18%	225

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EAM Investors's HBIO Position: Q3 2023 in Review

EAM Investors sold out of Harvard Bioscience (HBIO) in Q3 2023, closing a stake of 20,499 shares — an estimated $1.13M sold.

EAM Investors first reported a position in HBIO in Q1 2015 and held it in 9 quarters. The position peaked at $1.72M in Q2 2021. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2023.

EAM Investors reported no remaining Harvard Bioscience position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 20,499 Harvard Bioscience shares in Q3 2023, an estimated $1.13M.
EAM Investors first reported a position in Harvard Bioscience in Q1 2015 and held it in 9 quarters.
EAM Investors's Harvard Bioscience position peaked at $1.72M in Q2 2021.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.